Clinical trials
Secondary Acute Myeloid Leukemia clinical trials
Below are recruiting secondary acute myeloid leukemia clinical trials, each written for real people, not researchers. We’re tracking 122 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06152809RecruitingPhase 1
Immune cells with venetoclax for acute myeloid leukemia
This trial tests a combination of specially prepared immune cells (CIML NK cells) and a drug called venetoclax for people with acute myeloid leukemia (AML) or a related condition. The goal is to see if this treatment can help control the leukemia and possibly prepare for a stem cell transplant.
Boston, MassachusettsAges 18 years+ - NCT06917911RecruitingPhase 2
Testing two drug additions to standard chemotherapy for a type of acute myeloid leukemia
This trial tests whether adding venetoclax or gemtuzumab ozogamicin to the usual chemotherapy helps people with a specific genetic type of acute myeloid leukemia (AML) respond better. It may improve chances of remission.
Pembroke Pines, FloridaAges 18–59 - NCT06904066RecruitingPhase 1
Custom T cells for blood cancers with specific mutations
This trial tests a personalized treatment where your immune cells are collected, modified to recognize unique cancer markers (neoantigens) from TP53 or RAS mutations, and returned to fight blood cancers like AML, MDS, or multiple myeloma.
Bethesda, MarylandAges 18–120 - NCT07439211RecruitingPhase 1
Testing a new drug combo for acute myeloid leukemia
This trial tests a new drug, eganelisib, combined with azacitidine and venetoclax for patients with acute myeloid leukemia (AML). It's for people whose AML has come back or hasn't responded to treatment, or for those with a high-risk type who haven't been treated yet.
Boston, MassachusettsAges 18–90 - NCT06834282RecruitingPhase 1
A study of CER-1236 for certain blood cancers
This trial tests an experimental cell therapy called CER-1236 for people with acute myeloid leukemia, myelodysplastic syndrome, or myelofibrosis. It aims to see if it can help treat these cancers.
Sacramento, CaliforniaAges 18–85 - NCT05587049Recruiting
Testing an oral medicine plus azacitidine to improve AML disease
This study looks at how a standard AML treatment plan affects a person’s disease status over time. It focuses on newly diagnosed adults who cannot safely get intensive chemotherapy, using oral venetoclax plus azacitidine.
Medellín, AntioquiaAges 18 years+ - NCT07783100RecruitingPhase 2
Combination treatment for relapsed or refractory acute myeloid leukemia
This study tests a combination of three drugs (venetoclax, chidamide, and chiglitazar) for people with acute myeloid leukemia (AML) that has not responded to standard treatment or has returned. The goal is to see if this combination can help control the leukemia and is safe.
Xiamen, FujianAges 18 years+ - NCT07582172RecruitingPhase 2
Stem Cell Transplant for Hard-to-Treat Blood Cancers in Older Adults
This trial tests a new combination of radiation and chemotherapy to prepare your body for a stem cell transplant from a matched donor. It's designed for older patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that hasn't responded well to standard treatments.
Duarte, CaliforniaAges 18 years+ - NCT05886049RecruitingPhase 1
Testing a menin drug with standard chemo for newly diagnosed AML
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
Orange, CaliforniaAges 18–75 - NCT06466395RecruitingPhase 1
Hyper-CVAD plus venetoclax for relapsed pediatric leukemia
This trial tests a combination of chemotherapy drugs (hyper-CVAD) plus a targeted pill called venetoclax for children and young adults with a type of leukemia that has returned or not responded to treatment. The goal is to see if this combo can help control the leukemia.
Houston, TexasAges 2–21 - NCT05445154RecruitingPhase 1/Phase 2
New treatment for newly diagnosed FLT3 AML with oral drugs
This Phase 1/2 study tests SKLB1028 (with daunorubicin and cytarabine) in people with newly diagnosed acute myeloid leukemia (AML) who have an FLT3 mutation. It aims to see how well and how safely this treatment works for this specific type of AML.
ChengduAges 18–59 - NCT07237230Recruiting
Gamma-delta T cells to prevent leukemia relapse after transplant
This trial tests if a special type of immune cell called gamma-delta T cells can help prevent acute myeloid leukemia from coming back after a stem cell transplant. It is for people with high-risk features who have recently had a transplant.
Wuhan, HubeiAges 18–65 - NCT07743112RecruitingPhase 2
Study of a new drug combo for untreated acute myeloid leukemia
This trial tests a new drug, MAX-40279, combined with two standard treatments (venetoclax and azacitidine) for people with newly diagnosed acute myeloid leukemia who are not healthy enough for intensive chemotherapy. The goal is to see if adding this drug improves outcomes.
TianjinAges 18 years+ - NCT06287944RecruitingPhase 1
Targeted radiation and chemo before donor stem cell transplant
This trial tests a new approach: giving a targeted radioactive antibody (attached to a drug that finds CD38 on cancer cells) along with low-dose chemotherapy and targeted radiation to the bone marrow before a donor stem cell transplant. The goal is to prepare the body for the transplant while killing remaining cancer cells more precisely.
Duarte, CaliforniaAges 18–70 - NCT06764238RecruitingPhase 2/Phase 3
Treatment study for children with new B-cell ALL (intermediate/high risk)
This trial tests a treatment plan for children and teens newly diagnosed with B-cell acute lymphoblastic leukemia (ALL) that is intermediate or high risk. The goal is to find the best way to treat the cancer and improve outcomes.
Hefei, AnhuiAges 1 month–18 years - NCT04227847RecruitingPhase 1
Study of a CD70-targeting drug for blood cancer
This Phase 1 study tests the safety of SEA-CD70, a drug that targets CD70, in people with certain blood cancers like MDS and AML. It may help doctors learn whether this approach can be used safely for patients whose disease has come back or not responded to standard treatments.
Birmingham, AlabamaAges 18 years+ - NCT07250646RecruitingPhase 1
Rebecsinib for secondary AML or high-risk myelofibrosis
This trial tests a new drug called rebecsinib for people with a certain type of leukemia (secondary acute myeloid leukemia) or a high-risk bone marrow disorder (myelofibrosis) that has come back or not responded to other treatments. The goal is to see if it works and is safe.
Duarte, CaliforniaAges 18 years+ - NCT03113643RecruitingPhase 1
SL-401 with standard drugs for hard-to-treat blood cancers
This Phase 1 study tests SL-401, given with azacitidine and sometimes venetoclax, to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN). It aims to find a safe dose and see whether the combination can improve blood cancer control.
Duarte, CaliforniaAges 18 years+ - NCT03439371Recruiting
Micro-transplant treatment for older adults with AML in remission
This trial studies a gentler (“micro-”) transplant approach for people ages 60–74 with acute myeloid leukemia (AML) who are in remission and cannot safely have the usual stronger transplant conditioning. It may help reduce transplant risks while keeping the leukemia under control.
Clermont-FerrandAges 60–75 - NCT03586609RecruitingPhase 2
New treatment for older adults with untreated AML
This Phase 2 trial tests a combination of venetoclax, cladribine, low-dose cytarabine, and azacitidine in people with untreated acute myeloid leukemia (AML). It may help shrink the leukemia and improve blood counts by trying a stronger, multi-drug approach.
Houston, TexasAges 50 years+ - NCT03629171RecruitingPhase 2
Venetoclax plus chemo to treat certain AML types
This trial tests a combination of venetoclax with liposome chemotherapy (daunorubicin and cytarabine) for adults with acute myeloid leukemia (AML) that is back after treatment or not responding, and for some newly diagnosed cases. It aims to shrink leukemia and help more people achieve remission.
Houston, TexasAges 18 years+ - NCT03630991RecruitingPhase 1
Calcium chelator medicine for AML or MDS during chemotherapy
This Phase 1 study tests whether edetate calcium disodium (also called succimer) can be safely given to people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) while they are on chemotherapy. The goal is to learn the safest dose and whether it has signs of helping the blood cancer respond to treatment.
Houston, TexasAges 1 year+ - NCT03850574RecruitingPhase 1/Phase 2
Tuspetinib for relapsed or hard-to-treat AML
This early-phase study tests tuspetinib in people with AML that has come back or did not respond to treatment. The goal is to learn whether it is safe and tolerable, how the drug behaves in the body, and whether it shows signs of benefit.
Birmingham, AlabamaAges 18 years+ - NCT04024761RecruitingPhase 1
NK cell therapy for leukemia relapse after transplant
This Phase 1 study tests whether an infusion of special immune cells (NK cells) from a donor can help control leukemia or related blood cancers that come back or do not fully go away after a stem cell transplant. It also uses short chemotherapy to “make space” for the NK cells to work, and IL-2 to help them function.
Boston, MassachusettsAges 12 years+
Hear when a new Secondary Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Secondary Acute Myeloid Leukemia trials by city
Studies with a site in or near these metro areas.
Secondary Acute Myeloid Leukemia trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for secondary acute myeloid leukemia?
- Yes. Clin2 currently lists 122 recruiting secondary acute myeloid leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a secondary acute myeloid leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a secondary acute myeloid leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.